United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - vasopressin (unii: y87y826h08) (vasopressin - unii:y87y826h08) - vasopressin 20 [usp'u] in 1 ml - vasopressin injection, usp is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus. anaphylaxis or hypersensitivity to the drug or its components.

United States - English - NLM (National Library of Medicine)

feneral injectables & vaccines, inc - vasopressin (unii: y87y826h08) (vasopressin - unii:y87y826h08) - vasopressin 20 [usp'u] in 1 ml - vasopressin injection, usp is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus. anaphylaxis or hypersensitivity to the drug or its components.

United States - English - NLM (National Library of Medicine)

american regent, inc. - vasopressin (unii: y4907o6mfd) (vasopressin - unii:y4907o6mfd) - vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin injection 1 ml single-dose vial and 10 ml multiple-dose vial are contraindicated in patients with known allergy or hypersensitivity to 8-l-arginine vasopressin or chlorobutanol.  risk summary there are no available data on vasopressin injection use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with vasopressin. clinical considerations dose adjustments during pregnancy and the postpartum period because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin injection may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)].  maternal adverse reactions vasopressin injection may produce tonic uterine contractions. vasopressin receptors are

United States - English - NLM (National Library of Medicine)

dr. reddys laboratories inc - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin injection 1 ml single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasopressin injection use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin injection may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)] . maternal adverse reactions:  vasopressin injection may produce tonic uterine contractions that could threaten the continuation

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - vasopressin (unii: y4907o6mfd) (vasopressin - unii:y4907o6mfd) - vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin injection 10 ml multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8-l-arginine vasopressin or chlorobutanol. the 1 ml single-dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasopressin use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)] . maternal adverse reactions: vasopressin may produce tonic uterine contractions that could threaten the continuation of pregnancy. there are no data on the presence of vasopressin injection in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. safety and effectiveness of vasopressin in pediatric patients with vasodilatory shock have not been established. clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see warnings and precautions (5), adverse reactions (6), and clinical pharmacology (12.3)] .

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin injection 1 ml single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. 8.1 pregnancy risk summary there are no available data on vasopressin injection use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin injection may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)]. maternal adverse reactions: vasopressin injection may produce tonic uterine contractions that could threaten

United States - English - NLM (National Library of Medicine)

amphastar pharmaceuticals, inc. - vasopressin (unii: y4907o6mfd) (argipressin - unii:y4907o6mfd) - vasopressin injection, usp is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin injection, usp 1 ml single dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑l-arginine vasopressin or chlorobutanol. risk summary there are no available data on vasopressin injection, usp use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with vasopressin. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin injection, usp may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3) ]. maternal adverse reactions : vasopressin injection, usp may produce tonic uterine contractions that could threaten th

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin injection is contraindicated in patients with known allergy or hypersensitivity to 8-l-arginine vasopressin or chlorobutanol. 8.1 pregnancy risk summary there are no available data on vasopressin use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with vasopressin. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)]. maternal adverse reactions: vasopressin may produce tonic uterine contractions that could threaten the continuation of pregnancy. 8.2 lactation there are no data on the presence of vasopressin injection in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. 8.4 pediatric use safety and effectiveness of vasopressin in pediatric patients with vasodilatory shock have not been established. 8.5 geriatric use clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see warnings and precautions (5), adverse reactions (6), and clinical pharmacology (12.3)].

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - vasopressin (unii: y4907o6mfd) (vasopressin - unii:y4907o6mfd) - vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin injection 1 ml single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasopressin injection use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin injection may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)]. maternal adverse reactions: vasopressin injection may produce tonic uterine contractions that could threaten the continuation

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - vasopressin (unii: y4907o6mfd) (vasopressin - unii:y4907o6mfd) - vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin injection 1 ml single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasopressin injection use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin injection may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)]. maternal adverse reactions: vasopressin injection may produce tonic uterine contractions that could threaten the continuation